{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:00:55Z","timestamp":1768341655813,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.canrad.2018.05.006","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T02:17:59Z","timestamp":1553134679000},"page":"147-150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prise en charge des patients atteints de m\u00e9tastases c\u00e9r\u00e9brales de m\u00e9lanome"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2133-6454","authenticated-orcid":false,"given":"A.","family":"Modesto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-C.","family":"Sol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Lubrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boulinguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Sibaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Gomez-Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c9.","family":"Moyal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2018.05.006_bib0205","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0210","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.canrad.2014.11.010","article-title":"Traitement syst\u00e9mique des m\u00e9tastases c\u00e9r\u00e9brales de m\u00e9lanome","volume":"19","author":"Le Rhun","year":"2015","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.05.006_bib0220","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0225","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.ijrobp.2017.06.2454","article-title":"Estimating survival in melanoma patients with brain metastases: an update of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA)","volume":"99","author":"Sperduto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.006_bib0230","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","article-title":"Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2\u00a0trial","volume":"18","author":"Davies","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0235","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2\u00a0trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0240","doi-asserted-by":"crossref","first-page":"9508","DOI":"10.1200\/JCO.2017.35.15_suppl.9508","article-title":"A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients with melanoma brain metastases: the anti-PD1\u00a0brain collaboration","volume":"35","author":"Long","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0245","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2017.35.15_suppl.9507","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with melanoma metastatic to the brain: results of the phase II study checkmate 204","volume":"35","author":"Tawbi","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0250","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.canrad.2014.11.006","article-title":"Recommandations de l\u2019Anocef pour la prise en charge des m\u00e9tastases c\u00e9r\u00e9brales","volume":"19","author":"Le Rhun","year":"2015","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.05.006_bib0255","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2015.05.001","article-title":"Interval from imaging to treatment delivery in the radiation surgery age: how long is too long?","volume":"93","author":"Seymour","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.006_bib0260","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.canrad.2012.04.003","article-title":"Radioth\u00e9rapie st\u00e9r\u00e9otaxique intracr\u00e2nienne\u00a0: prescription de la dose","volume":"16","author":"Schlienger","year":"2012","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.05.006_bib0265","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.canrad.2016.07.041","article-title":"Radioth\u00e9rapie des m\u00e9tastases c\u00e9r\u00e9brales","volume":"20","author":"Latorzeff","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.05.006_bib0270","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3\u00a0trial","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0275","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0360-3016(99)00507-6","article-title":"Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05","volume":"47","author":"Shaw","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.006_bib0280","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.ijrobp.2009.06.006","article-title":"Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery","volume":"77","author":"Blonigen","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.006_bib0285","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.canrad.2013.06.027","article-title":"Hypofractionnement en radioth\u00e9rapie\u00a0: l\u2019\u00e9ternel retour","volume":"17","author":"Cosset","year":"2013","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.05.006_bib0290","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multifraction (3\u00d79Gy) stereotactic radiosurgery for large (>2cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis","volume":"95","author":"Minniti","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.006_bib0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canrad.2014.11.007","article-title":"Place de la chirurgie dans la prise en charge des m\u00e9tastases c\u00e9r\u00e9brales","volume":"19","author":"M\u00e9tellus","year":"2015","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2018.05.006_bib0300","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001\u00a0study","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0305","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1001\/jama.280.17.1485","article-title":"Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial","volume":"280","author":"Patchell","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2018.05.006_bib0310","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC.3): a multicentre, randomised, controlled, phase 3\u00a0trial","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0315","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ijrobp.2013.03.037","article-title":"Multidose stereotactic radiosurgery (9Gy\u00d73) of the postoperative resection cavity for treatment of large brain metastases","volume":"86","author":"Minniti","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.006_bib0320","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11060-017-2394-z","article-title":"Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases","volume":"132","author":"Minniti","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0325","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1470-2045(14)70061-0","article-title":"Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study","volume":"15","author":"Yamamoto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0330","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ijrobp.2017.04.037","article-title":"A multi-institutional prospective observational study of stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901\u00a0Study Update): irradiation-related complications and long-term maintenance of mini-mental state examination scores","volume":"99","author":"Yamamoto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2018.05.006_bib0335","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1200\/JCO.2011.41.0639","volume":"31","author":"Soffietti","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0340","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"Mulvenna","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.canrad.2018.05.006_bib0345","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/CMR.0000000000000268","article-title":"B-raf inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis","volume":"26","author":"Patel","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.canrad.2018.05.006_bib0350","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/annonc\/mdv139","article-title":"Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients","volume":"26","author":"Hecht","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0355","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJMoa1112824","article-title":"Immunologic correlates of the abscopal effect in a patient with melanoma","volume":"366","author":"Postow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2018.05.006_bib0360","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2016.03.067","article-title":"Can immunostimulatory agents enhance the abscopal effect of radiotherapy?","volume":"62","author":"L\u00e9vy","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2018.05.006_bib0365","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of Local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0370","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/annonc\/mdv622","article-title":"Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1\u00a0therapy","volume":"27","author":"Ahmed","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0375","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/CMR.0000000000000386","article-title":"Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1\u00a0therapy: a safe and effective combination","volume":"27","author":"Aboudaram","year":"2017","journal-title":"Melanoma Res"},{"key":"10.1016\/j.canrad.2018.05.006_bib0380","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","article-title":"Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery","volume":"23","author":"Mathew","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.canrad.2018.05.006_bib0385","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/cncr.30138","article-title":"Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery","volume":"122","author":"Qian","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.canrad.2018.05.006_bib0390","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ejca.2017.01.007","article-title":"Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies","volume":"75","author":"Choong","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.canrad.2018.05.006_bib0395","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1093\/annonc\/mdx408","article-title":"Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy","volume":"28","author":"Tallet","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.canrad.2018.05.006_bib0200","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ejrad.2008.08.009","article-title":"Morphological and functional MRI, MRS, perfusion and diffusion changes after radiosurgery of brain metastasis","volume":"72","author":"Kang","year":"2009","journal-title":"Eur J Radiol"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819300216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321819300216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:29:12Z","timestamp":1761136152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321819300216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1278321819300216"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2018.05.006","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge des patients atteints de m\u00e9tastases c\u00e9r\u00e9brales de m\u00e9lanome","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2018.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}